GlaxoSmithKline Pharmaceuticals today reported a 27.45 per cent rise in its standalone net profit at Rs 128.67 crore for the third quarter ended September.
The company had posted a net profit of Rs 100.95 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
The standalone total income from operations also rose to Rs 746.76 crore for the quarter under consideration from Rs 626.65 crore for the same period year-ago, it added.
The company follows the January-December financial year.
Established in 1924 in India, GlaxoSmithKline Pharmaceuticals’ product portfolio includes prescription medicines and vaccines.
The company’s prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.